PRINCETON, New Jersey, October 28 /PRNewswire/ --
- Laureate To Manufacture Tolera's Monoclonal Antibody Product Candidate -
Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Tolera Therapeutics, Inc., a biotechnology company that develops and offers targeted therapies and safer solutions for immune modulation and related medical needs. According to the agreement, Laureate will produce Tolera's TOL101 monoclonal antibody under cGMP conditions to be used in clinical trials. Terms of the manufacturing agreement were not disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )
We are pleased to work closely with Tolera to accelerate their antibody therapeutics program to clinic, said Robert J. Broeze, Ph. D., President Chief Executive Officer of Laureate. We are committed to providing Tolera with superior services to help them achieve their manufacturing objectives.
We are excited to work with Laureate, a company with demonstrated expertise in biopharmaceutical manufacturing. Their capabilities in both clinical and commercial-grade materials can support our aggressive development and commercial plans, said John J. Puisis, President and Chief Executive Officer of Tolera. We look forward to our partnership with Laureate in utilizing their specialized experience in the manufacture of monoclonal antibodies.
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development and protein production company located in Princeton, New Jersey. Laureate Pharma offers superior bioprocessing services that accelerate new products from development through production. Laureate provides a wide range of specialized services from process design and development to full-scale cGMP production, purification, aseptic filling, testing, validation, analytical services, and regulatory support. Laureate is focused on two active segments of the biopharmaceutical industry: monoclonal antibodies and recombinant protein products. For more information, contact Michael Cavanaugh, Vice President Sales, Marketing, and Business Development at +1-609-919-3400, or info@laureatepharma.com or visit www.laureatepharma.com.
About Tolera Therapeutics, Inc.
Tolera Therapeutics is a biotechnology company developing novel therapies for patients and doctors providing more targeted and safer clinical solutions for immune modulation and related therapies. The company recently closed its Series A round and intends to commercialize its lead therapeutic agent TOL101 (T-cell modulation) for acute rejection in kidney transplantation, followed by additional development and commercialization in autoimmune and oncology applications. For further information, visit www.tolera.com.
Web site: http://www.laureatepharma.com http://www.tolera.com
Michael Cavanaugh, Vice President Sales, Marketing, and Business Development of Laureate Pharma, Inc., +1-609-919-3400, info@laureatepharma.com. Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO, AP Archive: http://photoarchive.ap.org, PRN Photo Desk, photodesk@prnewswire.com
Comments